Clinical Trial Update: A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating IN10018 in combination with D-1553 versus standard therapy as first-line treatment for non-squamous non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• D-1553
• IN10018

Snippet

Sponsor: InxMed (Shanghai) Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING